Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Tahl CindySEE REMARKS | Fate TherapeuticsFATE | Open-market sale | 05/20 | 05/21 | 25,590 sh | $1.88 | $48,109.2 | −3.9% |
Valamehr BahramPresident and CEO | Fate TherapeuticsFATE | Open-market sale | 05/20 | 05/21 | 28,946 sh | $1.88 | $54,418.48 | −4.4% |
Tahl CindySEE REMARKS | Fate TherapeuticsFATE | Open-market sale | 01/09 | 01/12 | 10,589 sh | $1.06 | $11,224.34 | −2.7% |
Valamehr BahramPresident and CEO | Fate TherapeuticsFATE | Open-market sale | 01/09 | 01/12 | 5,190 sh | $1.07 | $5,553.3 | −1.5% |
Tahl CindySEE REMARKS | Fate TherapeuticsFATE | Open-market sale | 25/08/04 | 25/08/05 | 9,037 sh | $1.06 | $9,579.22 | −2.2% |
Valamehr BahramPresident and CEO | Fate TherapeuticsFATE | Open-market sale | 25/08/04 | 25/08/05 | 14,466 sh | $1.06 | $15,333.96 | −4.1% |
Tahl CindySEE REMARKS | Fate TherapeuticsFATE | Open-market sale | 25/01/10 | 25/01/13 | 5,654 sh | $1.55 | $8,763.7 | −1.7% |
Valamehr BahramPresident and CEO | Fate TherapeuticsFATE | Open-market sale | 25/01/10 | 25/01/13 | 8,705 sh | $1.54 | $13,405.7 | −2.4% |
Bressi Jerome CharlesSEE REMARKS | Fate TherapeuticsFATE | Open-market sale | 25/01/10 | 25/01/13 | 5,980 sh | $1.55 | $9,269 | −2.2% |
Redmile GroupDirector | Fate TherapeuticsFATE | Open-market buy | 24/12/20 | 24/12/26 | 397,964 sh | $1.68 | $668,579.52 | +3.2% |
Redmile GroupDirector | Fate TherapeuticsFATE | Open-market sale | 24/12/20 | 24/12/26 | 341,633 sh | $1.68 | $573,943.44 | −2.7% |
Yuan XuDirector | Fate TherapeuticsFATE | Open-market sale10b5-1 plan | 24/08/06 | 24/08/07 | 633 sh | $4.23 | $2,677.59 | −6.8% |
Fate TherapeuticsFATE | Open-market sale10b5-1 plan | 24/03/04 | 24/03/05 | 2,447 sh | $7.77 | $19,013.19 | −2.4% | |
Fate TherapeuticsFATE | Open-market sale10b5-1 plan | 24/01/29 | 24/01/30 | 1,849 sh | $5.00 | $9,245 | −1.7% | |
Wolchko J. ScottPresident and CEO | Fate TherapeuticsFATE | Open-market sale | 24/01/09 | 24/01/10 | 14,391 sh | $4.37 | $62,888.67 | −3.7% |
Tahl CindyGeneral Counsel and Secretary | Fate TherapeuticsFATE | Open-market sale | 24/01/09 | 24/01/10 | 10,874 sh | $4.37 | $47,519.38 | −7.1% |
Valamehr BahramChief R&D Officer | Fate TherapeuticsFATE | Open-market sale | 24/01/09 | 24/01/10 | 11,271 sh | $4.38 | $49,366.98 | −6.7% |
Fate TherapeuticsFATE | Open-market sale | 24/01/09 | 24/01/10 | 7,028 sh | $4.37 | $30,712.36 | −6.2% | |
Fate TherapeuticsFATE | Open-market sale10b5-1 plan | 24/01/02 | 24/01/03 | 5,182 sh | $3.66 | $18,966.12 | −4.4% | |
Redmile GroupDirector | Fate TherapeuticsFATE | Open-market buy | 23/12/26 | 23/12/28 | 44,630 sh | $3.72 | $166,023.6 | +0.3% |
